The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report

Background. Lung cancer (LC) occupies a leading position among malignant tumors in the world, it accounts for 11.4% of the total malignant neoplasms. In 2020, there were 2 206 771 new cases of LC and 1 796 144 deaths worldwide. Among the histological variants, small cell LC (SCLC) has the most unfav...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikolai A. Ognerubov, Tatyana S. Antipova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	small cell lung cancer pd-1/pd-l1 checkpoint inhibitors atezolizumab combined positron emission and x-ray computed tomography Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/18767e92e2ff4b289303c8325dfb01d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:18767e92e2ff4b289303c8325dfb01d9
record_format	dspace
spelling	oai:doaj.org-article:18767e92e2ff4b289303c8325dfb01d92021-11-30T16:55:01ZThe use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report1815-14341815-144210.26442/18151434.2021.2.200965https://doaj.org/article/18767e92e2ff4b289303c8325dfb01d92021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/72330/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Background. Lung cancer (LC) occupies a leading position among malignant tumors in the world, it accounts for 11.4% of the total malignant neoplasms. In 2020, there were 2 206 771 new cases of LC and 1 796 144 deaths worldwide. Among the histological variants, small cell LC (SCLC) has the most unfavorable outcomes. This variant is considered highly sensitive to chemotherapy. Despite some successes in the treatment of this disease, the results of treatment remain problematical. In recent years, the use of immune checkpoint inhibitors has provided significant control of the course of the disease. Aim. To show the efficacy of atezolizumab in combination with chemotherapy in patients with metastatic SCLC. Materials and methods. A 76-year-old patient with left lung cancer, IVA T4N3M1b, the right supraclavicular lymph node metastases, exudative pleuritis of the left lung was under observation. The histological investigation showed SCLC. Brain metastases were not detected. ECOG 0. Results. The patient was treated using atezolizumab 1200 mg in combination with carboplatin 5 AUC and etoposide 100 mg/m2 on days 1, 2, 3 for four cycles, followed by a maintenance therapy regimen with atezolizumab 1200 mg every 21 days. The patient received 21 injections during 14 months. The assessment of treatment effect was evaluated using combined 18F-fluorodeoxyglucose positron emission and X-ray computed tomography. As a result of the treatment, after 7 months, a complete clinical and morpho-metabolic regression of the tumor was reached, which persisted throughout the period of the treatment. Among the adverse events were detected grade 2 anemia and first-stage sensory neuropathy. No immune-related adverse events were observed. Conclusion. The addition of atezolizumab to etoposide + carboplatin as the first-line therapy for extensive-stage SCLC provides the long-term overall and disease-free survival with achieving the satisfactory quality of life in patients and acceptable drug tolerance.Nikolai A. OgnerubovTatyana S. AntipovaIP Habib O.N.articlesmall cell lung cancerpd-1/pd-l1 checkpoint inhibitorsatezolizumabcombined positron emission and x-ray computed tomographyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 292-298 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	small cell lung cancer pd-1/pd-l1 checkpoint inhibitors atezolizumab combined positron emission and x-ray computed tomography Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	small cell lung cancer pd-1/pd-l1 checkpoint inhibitors atezolizumab combined positron emission and x-ray computed tomography Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nikolai A. Ognerubov Tatyana S. Antipova The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
description	Background. Lung cancer (LC) occupies a leading position among malignant tumors in the world, it accounts for 11.4% of the total malignant neoplasms. In 2020, there were 2 206 771 new cases of LC and 1 796 144 deaths worldwide. Among the histological variants, small cell LC (SCLC) has the most unfavorable outcomes. This variant is considered highly sensitive to chemotherapy. Despite some successes in the treatment of this disease, the results of treatment remain problematical. In recent years, the use of immune checkpoint inhibitors has provided significant control of the course of the disease. Aim. To show the efficacy of atezolizumab in combination with chemotherapy in patients with metastatic SCLC. Materials and methods. A 76-year-old patient with left lung cancer, IVA T4N3M1b, the right supraclavicular lymph node metastases, exudative pleuritis of the left lung was under observation. The histological investigation showed SCLC. Brain metastases were not detected. ECOG 0. Results. The patient was treated using atezolizumab 1200 mg in combination with carboplatin 5 AUC and etoposide 100 mg/m2 on days 1, 2, 3 for four cycles, followed by a maintenance therapy regimen with atezolizumab 1200 mg every 21 days. The patient received 21 injections during 14 months. The assessment of treatment effect was evaluated using combined 18F-fluorodeoxyglucose positron emission and X-ray computed tomography. As a result of the treatment, after 7 months, a complete clinical and morpho-metabolic regression of the tumor was reached, which persisted throughout the period of the treatment. Among the adverse events were detected grade 2 anemia and first-stage sensory neuropathy. No immune-related adverse events were observed. Conclusion. The addition of atezolizumab to etoposide + carboplatin as the first-line therapy for extensive-stage SCLC provides the long-term overall and disease-free survival with achieving the satisfactory quality of life in patients and acceptable drug tolerance.
format	article
author	Nikolai A. Ognerubov Tatyana S. Antipova
author_facet	Nikolai A. Ognerubov Tatyana S. Antipova
author_sort	Nikolai A. Ognerubov
title	The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
title_short	The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
title_full	The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
title_fullStr	The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
title_full_unstemmed	The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
title_sort	use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. case report
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/18767e92e2ff4b289303c8325dfb01d9
work_keys_str_mv	AT nikolaiaognerubov theuseofatezolizumabincombinationwithchemotherapyinfirstlineofmetastaticsmallcelllungcancercasereport AT tatyanasantipova theuseofatezolizumabincombinationwithchemotherapyinfirstlineofmetastaticsmallcelllungcancercasereport AT nikolaiaognerubov useofatezolizumabincombinationwithchemotherapyinfirstlineofmetastaticsmallcelllungcancercasereport AT tatyanasantipova useofatezolizumabincombinationwithchemotherapyinfirstlineofmetastaticsmallcelllungcancercasereport
_version_	1718406429512040448

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report

Ejemplares similares